NCT06320223 PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer
| NCT ID | NCT06320223 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Essen |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2024-03-05 |
| Primary Completion | 2034-03-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2024-03-05 with a primary completion date of 2034-03-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: PROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome. Need: Improved prognostication across various stages of prostate cancer is needed for management guidance and study design. Aim: 1. To assess the prognostic value of PSMA PET 2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages Inclusion: * Adult patients with * biopsy/histo proven prostate cancer who * underwent PSMA PET (any type) * for staging or re-staging at any stage and who * have at least 3-year overall survival follow-up data available will be included consecutively. Exclusion: * Patients with neuroendocrine prostate cancer * Patients with metastasized or disseminated malignancy other than prostate cancer
Eligibility Criteria
Inclusion: * Adult patients with * biopsy/histo proven prostate cancer who * underwent PSMA PET (any type) * for staging or re-staging at any stage and who * have at least 3-year overall survival follow-up data available will be included consecutively. Exclusion: * Patients with neuroendocrine prostate cancer * Patients with metastasized or disseminated malignancy other than prostate cancer.
Contact & Investigator
Wolfgang P Fendler, M.D.
PRINCIPAL INVESTIGATOR
University Hospital, Essen
Frequently Asked Questions
Who can join the NCT06320223 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06320223 currently recruiting?
Yes, NCT06320223 is actively recruiting participants. Contact the research team at redcap@ikim.nrw for enrollment information.
Where is the NCT06320223 trial being conducted?
This trial is being conducted at Essen, Germany.
Who is sponsoring the NCT06320223 clinical trial?
NCT06320223 is sponsored by University Hospital, Essen. The principal investigator is Wolfgang P Fendler, M.D. at University Hospital, Essen. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.